epoetin alfa
- Generic Name
- epoetin alfa
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
- Conditions
- AnemiaCancer
- Locations
- 🇺🇸
Madigan Army Medical Center Urology Services, Tacoma, Washington, United States
🇺🇸Hanover Medical Specialists, PA, Wilmington, North Carolina, United States
🇺🇸Advanced Urology Medical Center, Anaheim, California, United States
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
- Conditions
- AnemiaLeukemiaLymphomaPrecancerous/Nonmalignant ConditionUnspecified Adult Solid Tumor, Protocol SpecificLymphoproliferative DisorderMultiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00070382
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery
- Conditions
- Stomach NeoplasmsRectal Neoplasms
- First Posted Date
- 2002-05-10
- Last Posted Date
- 2011-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT00036400
The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ortho Pharmaceuticals
- Registration Number
- NCT00002302
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Ortho Pharmaceutical Corp, Raritan, New Jersey, United States
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00002281
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00002255
- Locations
- 🇺🇸
UCLA Med Ctr, Los Angeles, California, United States
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ortho Pharmaceuticals
- Registration Number
- NCT00002042
- Locations
- 🇺🇸
Ortho Pharmaceutical Corp, Raritan, New Jersey, United States
The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ortho Pharmaceuticals
- Registration Number
- NCT00002303
- Locations
- 🇺🇸
Ortho Pharmaceutical Corp, Raritan, New Jersey, United States
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ortho Pharmaceuticals
- Registration Number
- NCT00002071
- Locations
- 🇺🇸
Ortho Pharmaceutical Corp, Raritan, New Jersey, United States
Treatment Program for Anemia in AIDS Patients
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- R W Johnson Pharmaceutical Research Institute
- Registration Number
- NCT00002022
- Locations
- 🇺🇸
R W Johnson Pharmaceutical Research Institute, Raritan, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.